Herantis Pharma Oyj reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net income was EUR 0.28 million compared to net loss of EUR 9.32 million a year ago. Basic earnings per share from continuing operations was EUR 0.02 compared to basic loss per share from continuing operations of EUR 0.64 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.42 EUR | -1.39% | +1.43% | -9.84% |
03-06 | Herantis Pharma Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-06 | Transcript : Herantis Pharma Oyj, 2023 Earnings Call, Mar 06, 2024 |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-9.84% | 30.77M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- HRTIS Stock
- News Herantis Pharma Oyj
- Herantis Pharma Oyj Reports Earnings Results for the Full Year Ended December 31, 2023